| Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. | |
| | |
MedLine Citation:
|
PMID: 20231062 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To assess the outcome in patients with olfactory neuroblastoma (ONB). METHODS AND MATERIALS: Seventy-seven patients treated for nonmetastatic ONB between 1971 and 2004 were included. According to Kadish classification, there were 11 patients with Stage A, 29 with Stage B, and 37 with Stage C. T-classification included 9 patients with T1, 26 with T2, 16 with T3, 15 with T4a, and 11 with T4b tumors. Sixty-eight patients presented with N0 (88%) disease. RESULTS: Most of the patients (n = 56, 73%) benefited from surgery (S), and total excision was possible in 44 patients (R0 in 32, R1 in 13, R2 in 11). All but five patients benefited from RT, and chemotherapy was given in 21 (27%). Median follow-up period was 72 months (range, 6-315). The 5-year overall survival (OS), disease-free survival (DFS), locoregional control, and local control were 64%, 57%, 62%, and 70%, respectively. In univariate analyses, favorable factors were Kadish A or B disease, T1-T3 tumors, no nodal involvement, curative surgery, R0/R1 resection, and RT-dose 54 Gy or higher. Multivariate analysis revealed that the best independent factors predicting the outcome were T1-T3, N0, R0/R1 resection, and total RT dose (54 Gy or higher). CONCLUSION: In this multicenter retrospective study, patients with ONB treated with R0 or R1 surgical resection followed by at least 54-Gy postoperative RT had the best outcome. Novel strategies including concomitant chemotherapy and/or higher dose RT should be prospectively investigated in this rare disease for which local failure remains a problem. |
| | |
Authors:
|
Mahmut Ozsahin; Guenther Gruber; Olimpia Olszyk; Omur Karakoyun-Celik; Berrin Pehlivan; David Azria; Martine Roelandts; Johannes H A M Kaanders; Mustafa Cengiz; Marco Krengli; Oscar Matzinger; Abderrahim Zouhair |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't Date: 2010-03-16 |
Journal Detail:
|
Title: International journal of radiation oncology, biology, physics Volume: 78 ISSN: 1879-355X ISO Abbreviation: Int. J. Radiat. Oncol. Biol. Phys. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-25 Completed Date: 2010-11-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7603616 Medline TA: Int J Radiat Oncol Biol Phys Country: United States |
Other Details:
|
Languages: eng Pagination: 992-7 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland. mahmut.ozsahin@chuv.ch |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Analysis of Variance Combined Modality Therapy / methods Disease-Free Survival Esthesioneuroblastoma, Olfactory / mortality, pathology, therapy* Female Humans Male Middle Aged Nasal Cavity / pathology Neoplasm Staging Nose Neoplasms / mortality, pathology, therapy* Radiotherapy Dosage Retrospective Studies Treatment Outcome Young Adult |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with co...
Next Document: Dosimetric Evaluation of Automatic Segmentation for Adaptive IMRT for Head-and-Neck Cancer.